Global Dermatophytic Onychomycosis Market 2016-2020

  • ID: 3623669
  • Report
  • Region: Global
  • 57 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abeona Therapeutics
  • Anacor Pharmaceuticals
  • Galderma
  • Hexima
  • Janssen Biotech
  • MediQuest Therapeutics
  • MORE
About Dermatophytic Onychomycosis

Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.

The analysts forecast the global dermatophytic onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global dermatophytic onychomycosis market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat and prevent onychomycosis.

The market is divided into the following segments based on geography:

- APAC
- EMEA
- Americas

The report, Global Dermatophytic Onychomycosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors:

- Anacor Pharmaceuticals
- Galderma
- Janssen Biotech
- Novartis
- Valeant Pharmaceuticals

Other prominent vendors:

- Abeona Therapeutics
- Allergan
- Elorac
- GlaxoSmithKline
- Hexima
- Hisamitsu Pharmaceutical
- Mayne Pharma
- MediQuest Therapeutics
- Meiji Seika Pharma
- Merz Pharma
- Moberg Pharma
- NanoBio
- NovaBiotics
- Nuvo Research
- Pfizer
- Polichem
- Promius Pharma
- Sanofi
- Seren Pharmaceuticals
- Taro Pharmaceutical
- Topica Pharmaceuticals
- Viamet Pharmaceuticals

Market drivers

- Increase in R&D
- For a full, detailed list, view the full report

Market challenges

- Adverse effects and limited efficacy of drugs
- For a full, detailed list, view the full report

Market trends

- Increased focus on combination therapies
- For a full, detailed list, view the full report

Key questions answered in this report

- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeona Therapeutics
  • Anacor Pharmaceuticals
  • Galderma
  • Hexima
  • Janssen Biotech
  • MediQuest Therapeutics
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Product offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Key buying criteria
PART 05: Overview: Dermatophytic onychomycosis
  • Types of dermatophytic onychomycosis
  • Risk factors
  • Management
  • Epidemiology
PART 06: Pipeline analysis
  • TDT 067
  • P-3058
  • MOB-015
  • VT-1161
  • Luliconazole solution, 10%
  • ME1111
  • NP213
  • HXP124
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by route of administration
  • Topical
  • Oral
PART 09: Geographical segmentation
  • Global dermatophytic onychomycosis market by geographical segmentation 2015-2020
  • Dermatophytic onychomycosis market in Americas
  • Dermatophytic onychomycosis market in EMEA
  • Dermatophytic onychomycosis market in APAC
PART 10: Market drivers
  • Increase in R&D
  • Growing prevalence of dermatophytic onychomycosis
  • Unmet medical needs
  • Rise in prevalence of diabetes
PART 11: Impact of drivers

PART 12: Market challenges
  • Adverse effects and limited efficacy of drugs
  • Lack of awareness
  • Increased availability of generics and alternative therapies
  • Product recalls by US FDA
PART 13: Impact of drivers and challenges

PART 14: Market trends
  • Increased focus on combination therapies
  • Outsourcing of drugs manufacturing
  • Increase in strategic alliances among vendors
  • Incorporation of novel technology for product development
PART 15: Vendor landscape
  • Competitive scenario
  • Anacor Pharmaceuticals
  • Galderma
  • Janssen Biotech
  • Novartis
  • Valeant Pharmaceuticals
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
PART 17: About Author

List of Exhibits

Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs
Exhibit 02: Percentage of population undergoing treatment globally 2015
Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis
Exhibit 04: Treatment algorithm for dermatophytic onychomycosis
Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview
Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Comparison of activity of topical medications for onychomycosis
Exhibit 09: Comparison of activity of oral medications for onychomycosis
Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015
Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015
Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015
Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)
Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)
Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)
Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: Anacor Pharmaceuticals: Key takeaways
Exhibit 22: Galderma: Key takeaways
Exhibit 23: Janssen Biotech: Key takeaways
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Valeant Pharmaceuticals: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abeona Therapeutics
  • Anacor Pharmaceuticals
  • Galderma
  • Hexima
  • Janssen Biotech
  • MediQuest Therapeutics
  • MORE
New Report Released: – Global Dermatophytic Onychomycosis Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Dermatophytic Onychomycosis Market: Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis and Valeant Pharmaceuticals

Other Prominent Vendors in the market are: Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals and Viamet Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “It has been found that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. For instance, a combination of amorolfine nail lacquer and oral terbinafine, the most commonly used combination therapy, has improved clinical efficiency and is more cost-effective than terbinafine alone. At times, the combination of surgery and systemic and topical therapies are also used. Sometimes, non-pharmacological approaches such as laser or mechanical treatment are also used in combination with topical and systemic therapy. Such trends will have a positive impact on the growth of the market.”

According to the report, the increase in R&D to develop drugs with disease-modifying properties and a better safety and efficacy profile drives the market.

Further, the report states that the side effects associated with dermatophytic onychomycosis drugs are a challenge to the market as they hamper the acceptance of advanced drugs to treat moderate to severe dermatophytic onychomycosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Anacor Pharmaceuticals
- Galderma
- Janssen Biotech
- Novartis
- Valeant Pharmaceuticals
- Abeona Therapeutics
- Allergan
- Elorac
- GlaxoSmithKline
- Hexima
- Hisamitsu Pharmaceutical
- Mayne Pharma
- MediQuest Therapeutics
- Meiji Seika Pharma
- Merz Pharma
- Moberg P
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll